NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2026)

NewAmsterdam Pharma (NAMS) has 5 years of Other Non-Current Liabilities data on file, last reported at $46.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 111.39% year-over-year to $46.6 million; the trailing twelve-month figure through Mar 2026 stood at $46.6 million (up 111.39% YoY), and the FY2025 full-year result was $53.4 million, up 2145.0% from the prior year.
• Other Non-Current Liabilities fell to $46.6 million in Q1 2026, from $53.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $53.4 million in Q4 2025 to a low of $7195.8 in Q4 2022.
• A 5-year average of $20.2 million and a median of $17.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Peak annual rise in Other Non-Current Liabilities reached 162752.0% in 2024, while the deepest fall reached 69.44% in 2024.
• Tracing NAMS's Other Non-Current Liabilities over 5 years: stood at $7195.8 in 2022, then soared by 108129.73% to $7.8 million in 2023, then sank by 69.44% to $2.4 million in 2024, then jumped by 2145.0% to $53.4 million in 2025, then retreated by 12.87% to $46.6 million in 2026.
• Business Quant data shows NAMS's Other Non-Current Liabilities at $46.6 million in Q1 2026, $53.4 million in Q4 2025, and $41.5 million in Q3 2025.